Pfizer’s Toluca facility in the State of Mexico is actively addressing regional vaccination rate declines. They’re leading an awareness campaign for their new 20-valent pneumococcal vaccine, which offers superior protection compared to their earlier version. This response follows a noticeable drop in Mexico’s vaccination coverage, where rates for children’s vaccines have slipped to between 78% and 80%, down from the 95% seen in past years.
A combination of global vaccine shortages and misinformation about vaccines contributes to this decline. The Toluca plant plays a crucial role in Pfizer’s Latin American operations by labeling, storing, and distributing medical products to ten countries, including Argentina, Brazil, and Chile. This facility supports Pfizer’s larger strategy to boost vaccine uptake in Mexico and throughout Latin America.
Pfizer has committed to investing between $12 million and $15 million annually in the Toluca operation. The plant employs 420 people and boasts a manufacturing capacity of 194 million units. This effort complements the Mexican government’s push to create a more supportive environment for clinical research, making Mexico more attractive for future investments from Pfizer.
For more information, you can visit the source.
- About the Author
- More info
Leave a Reply